Key facts
- · Type: Amendment first sale 2026-05-04 · Amount sold: $27.93M · Total offering: $30M · SEC filing
- · Type: New offering first sale 2026-05-04 · Amount sold: $26.43M · Total offering: $30M · SEC filing
- · Type: New offering first sale 2026-02-23 · Amount sold: $3.32M · Total offering: $4M · SEC filing
- · Type: New offering first sale 2023-02-03 · Amount sold: $2.31M · Total offering: $2.31M · SEC filing
Is Allyx Therapeutics, Inc. a real, registered company?
Allyx Therapeutics, Inc. is a registered filer with the SEC (CIK 1865257) and has filed since 2023-02-10. 4 filings are on record, the latest on 2026-10-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Allyx Therapeutics, Inc.?
Allyx Therapeutics, Inc.'s filings name Gregory Ho, Paul Fonteyne, Robert Bettigole and 5 more as its officers, directors or promoters.
How much has Allyx Therapeutics, Inc. raised?
Its new offerings report $32.06M sold across 3 offerings, as its own filings state.
Run the free check on Allyx Therapeutics, Inc. →
NEW HAVEN, CONNECTICUT
Biotechnology
4
$32.06M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-21 | Amendment first sale 2026-05-04 | $27.93M | $30M | details · SEC filing |
| 2026-05-11 | New offering first sale 2026-05-04 | $26.43M | $30M | details · SEC filing |
| 2026-03-03 | New offering first sale 2026-02-23 | $3.32M | $4M | details · SEC filing |
| 2023-02-10 | New offering first sale 2023-02-03 | $2.31M | $2.31M | SEC filing |
Want the whole picture on Allyx Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Allyx Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allyx Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Allyx Therapeutics, Inc.'s own filings with the SEC. The people those filings name are on the team page.